A5111682671- Bladder and Urothelial Cancer Treatments
- Prostate Cancer Diagnosis and Treatment
- Urinary and Genital Oncology Studies
- Prostate Cancer Treatment and Research
- Urological Disorders and Treatments
- Renal cell carcinoma treatment
- Urologic and reproductive health conditions
- Renal and related cancers
- Renal and Vascular Pathologies
- Urinary Bladder and Prostate Research
- Cancer Genomics and Diagnostics
- Epigenetics and DNA Methylation
- Cancer, Lipids, and Metabolism
- Ureteral procedures and complications
- Sexual Differentiation and Disorders
- Genital Health and Disease
- Hormonal and reproductive studies
- Pediatric Urology and Nephrology Studies
- Testicular diseases and treatments
- Colorectal Cancer Screening and Detection
- Reconstructive Surgery and Microvascular Techniques
- Esophageal Cancer Research and Treatment
- Multiple and Secondary Primary Cancers
- Organ Donation and Transplantation
- Genetic and Kidney Cyst Diseases
Universidade Federal de São Paulo
2025
Baylor College of Medicine
2013-2023
Dan L Duncan Comprehensive Cancer Center
2021-2023
Ben Taub Hospital
2021-2023
Harris Health System
2023
New York University
2007-2018
Memorial Sloan Kettering Cancer Center
2009-2014
Methodist Hospital
2014
The Prostate Centre
2012-2013
University of British Columbia
2012-2013
We studied 137 primary testicular germ cell tumors (TGCTs) using high-dimensional assays of genomic, epigenomic, transcriptomic, and proteomic features. These exhibited high aneuploidy a paucity somatic mutations. Somatic mutation only three genes achieved significance—KIT, KRAS, NRAS—exclusively in samples with seminoma components. Integrated analyses identified distinct molecular patterns that characterized the major recognized histologic subtypes TGCT: seminoma, embryonal carcinoma, yolk...
Current clinical judgment in bladder cancer (BC) relies primarily on pathological stage and grade. We investigated whether a molecular classification of tumor cell differentiation, based developmental biology approach, can provide additional prognostic information. Exploiting large preexisting gene-expression databases, we developed biologically supervised computational model to predict markers that correspond with BC differentiation. To mechanistic insight, assessed relative tumorigenicity...
Study Type – Diagnostic (exploratory cohort) Level of Evidence 2b What’s known on the subject? and What does study add? Improved patient selection for conservative management, neoadjuvant chemotherapy, and/or extended lymphadenectomy is urgently needed. We developed a highly accurate preoperative model to predict muscle‐invasive non‐organ‐confined upper tract urothelial carcinoma based standard imaging ureteroscopy features. OBJECTIVE • To create multivariable identify patients at risk...
Testosterone replacement therapy in men with prostate cancer is controversial, concern that testosterone can stimulate growth. We evaluated the safety and efficacy of hypogonadal treated radical prostatectomy.We performed a review 103 after prostatectomy (treatment group) 49 nonhypogonadal (reference group). There were 77 low/intermediate (nonhigh) risk 26 high included analysis. All transdermal testosterone, serum hormone, hemoglobin, hematocrit specific antigen for more than 36...
Data supporting neoadjuvant chemotherapy of high grade upper tract urothelial carcinoma are scant. In this multi-institution, prospective, phase II trial we investigated pathological complete responses after carcinoma.Patients with in whom nephroureterectomy was planned were assigned to 4 cycles accelerated methotrexate, vinblastine, doxorubicin and cisplatin those baseline creatinine clearance greater than 50 ml per minute or gemcitabine carboplatin 30 less. The study primary end point a...
To assess the impact of patient age on outcomes after radical nephroureterectomy (RNU) for upper tract urothelial carcinoma (UTUC).Data were collected 1453 patients treated with RNU at 13 centres. Pathological slides reviewed by dedicated genitourinary pathologists according to standardized criteria. Age was analysed both as a continuous and categorical variable (<50, n = 85; 50-59.9, 229; 60-69.9, 416; 70-79.9, 523; > or =80 years, 200). RESULTS Patients aged <50 years less likely have...
No AccessJournal of UrologyAdult Urology1 Jun 2009Effect Warm Ischemia Time During Laparoscopic Partial Nephrectomy on Early Postoperative Glomerular Filtration Rate Guilherme Godoy, Vigneshwaran Ramanathan, Jamie A. Kanofsky, Rebecca L. O'Malley, Basir U. Tareen, Samir S. Taneja, and Michael D. Stifelman GodoyGuilherme Godoy , RamanathanVigneshwaran Ramanathan KanofskyJamie Kanofsky O'MalleyRebecca O'Malley TareenBasir Tareen TanejaSamir Taneja StifelmanMichael View All Author...
No AccessJournal of UrologyAdult Urology1 Sep 2009Bosniak Category IIF Designation and Surgery for Complex Renal Cysts Rebecca L. O'Malley, Guilherme Godoy, Elizabeth M. Hecht, Michael D. Stifelman, Samir S. Taneja O'MalleyRebecca O'Malley , GodoyGuilherme Godoy HechtElizabeth Hecht StifelmanMichael Stifelman TanejaSamir View All Author Informationhttps://doi.org/10.1016/j.juro.2009.05.046AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints...
pT1 urothelial carcinoma of the bladder is a potentially aggressive cancer diathesis with heterogeneous clinical behaviors. We tested whether combination immunohistochemical markers could risk stratify cases at radical cystectomy.p53, p21, pRB, p27, survivin and Ki-67 staining was performed on representative specimens 80 patients treated cystectomy bilateral pelvic lymphadenectomy (median followup 61.6 months).p53 expression altered in 25% patients, p21 46%, pRB 39%, p27 35%, 49% 34%. On...
You have accessJournal of UrologyAdult Urology1 Apr 2022Durability Response to Primary Chemoablation Low-Grade Upper Tract Urothelial Carcinoma Using UGN-101, a Mitomycin-Containing Reverse Thermal Gel: OLYMPUS Trial Final ReportThis article is commented on by the following:Editorial Comment Surena F. Matin, Phillip M. Pierorazio, Nir Kleinmann, John L. Gore, Ahmad Shabsigh, Brian Hu, Karim Chamie, Guilherme Godoy, Scott G. Hubosky, Marcelino Rivera, Michael O'Donnell, Marcus Quek, Jay D....
No AccessJournal of UrologyAdult Urology1 Feb 2009Changes in Continence and Erectile Function Between 2 4 Years After Radical Prostatectomy Leonard Glickman, Guilherme Godoy, Herbert Lepor GlickmanLeonard Glickman , GodoyGuilherme Godoy LeporHerbert View All Author Informationhttps://doi.org/10.1016/j.juro.2008.10.019AboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissionsReprints ShareFacebookLinked InTwitterEmail Abstract Purpose: There is a paucity information...
We evaluated predictors of freedom from biochemical recurrence in patients with pelvic lymph node metastasis at radical prostatectomy.Of 207 treated prostatectomy and bilateral dissection 45 received adjuvant androgen deprivation therapy 162 did not. Cox proportional hazards regression models were used to investigate after prostatectomy. Recurrence probability was estimated using the Kaplan-Meier method.A median 13 nodes removed. Of 122 had 1, 44 2 41 3 or greater positive nodes. without 103...
Abstract Purpose: The aim of the current study was to externally validate value survivin as a prognostic marker for bladder cancer in large multi-institutional cohort patients treated with radical cystectomy. Methods: comprised 726 cystectomy and bilateral pelvic lymphadenectomy. Survivin staining scoring were done automated systems coupled advanced color detection software. Specimens showing at least 10 reactivity considered altered. Predictive accuracy quantified using concordance index...
To determine whether the number and location of positive surgical margins (PSMs) in radical prostatectomy (RP) specimens affect biochemical recurrence (BCR) rates.The locations PSMs were recorded for 1308 consecutive men who underwent RP between October 2000 December 2006. BCR was defined as three prostate-specific antigen (PSA) level rises with peak >or=0.15 ng/mL. Multivariate regression analyses used to identify preoperative predictors BCR. The estimated 5-year risk calculated using...
We describe the cancer related outcome in patients with pT0 bladder urothelial carcinoma at radical cystectomy who did not receive preoperative chemotherapy a large multicenter series. also compared outcomes to those other stages and assessed effect of clinical stage on outcome.We reviewed records 4,430 treated for without neoadjuvant 12 centers United States, Canada Europe.Of 228 (5.1%) had disease cystectomy. Clinical was cTa or cTis 13.6% cT1 29.8% these patients, muscle invasive (cT2-4a)...